Recursion Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Recursion Pharmaceuticals, Inc.
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
The German group is putting another €1.3bn into its Leaps by Bayer investment arm until the end of 2024 to support new companies that are "shifting core paradigms in the sectors of health and agriculture."
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
- Artificial Intelligence
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Recursion Pharmaceuticals, LLC